| Issue Date | Title | Author(s) |
| 2016 | Epidemiology and treatment of invasive fungal diseases in patients with multiple myeloma: findings from a multicenter prospective study from China | Liu, Junru; Huang, He; Li, Yan; Liu, Lin; Li, Jianyong; Liu, Zhuogang; Lu, Jin; Ouyang, Jian; Song, Yongping; Zhou, Daobin; Ren, Hanyun; Ma, Jun; Wang, Chun; Yu, Li; Zhou, Jin; Wang, Jianmin; Xiao, Yang; Huang, Xiaojun; Li, Juan |
| 2018 | FINAL Results of an Phase, Multicenter, Randomied, Controlled OPEN LEVEL Trial: Decitabine Therapy in Patients with Myelodysplastic Syndromes | Shao, Zonghong; Liu, Hui; Jiang, Hao; Tong, Hongyan; Xiang, Ruixiang; Yang, Linhua; Zhao, Hongguo; Ouyang, Jian; Bai, Hai; Sun, Hui; Hou, Li; Jiang, Ming; Yun, Zeng; Liu, Zhuogang; Liang, Aibin; Xie, Yinghua; Yu, Kang; Zhai, Zhimin; Liu, Li |
| 20-May-2020 | Gls-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary impressive result of a phase II clinical trial. | Song, Yuqin; Zhu, Jun; Lin, Ningjing; Zhang, Mingzhi; Bai, Hai; Liu, Hui; Cui, Jie; Ke, Xiaoyan; Zhang, Huilai; Liu, Lihong; Yan, Dongmei; Jiang, Yongsheng; Zang, Aimin; Qi, Junyuan; Wang, Li; Liu, Zhuogang; Xu, Bing; Zhang, Ying; Zhang, Zhihui; Meng, Haijin |
| 15-Nov-2022 | Is the 2nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study | Yang, Sen; Zhang, Xiaoshuai; Zhang, Yanli; Du, Xin; Weng, Jianyu; Zhu, Huanling; Pan, Ling; Yang, Yun-fan; Meng, Li; Liu, Zhenfang; Liu, Xiaoli; Xu, Na; Chen, Chunyan; Wang, Xiaodong; Liang, Rong; Huang, Jian; Li, Guohui; Liu, Chunshui; Lin, Hai; Hu, Jianda; Fei, Li; Liu, Bingcheng; Li, Weiming; Liu, Zhuogang; Yang, Wei; Huang, Xiao Jun; Jiang, Qian |
| 15-Nov-2022 | A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy | Zhang, Xiaoshuai; Liu, Bingcheng; Huang, Jian; Zhang, Gongli; Liu, Xiaoli; Xu, Na; Li, Weiming; Du, Xin; Weng, Jianyu; Lin, Hai; Liang, Rong; Chen, Chunyan; Zhu, Huanling; Pan, Ling; Yang, Yun-fan; Wang, Xiaodong; Li, Guohui; Liu, Zhuogang; Liu, Zhenfang; Hu, Jianda; Liu, Chunshui; Fei, Li; Yang, Wei; Meng, Li; Gale, Robert Peter; Huang, Xiao Jun; Jiang, Qian |
| 15-Nov-2022 | Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor | Zhang, Xiaoshuai; Liu, Bingcheng; Huang, Jian; Zhang, Gongli; Liu, Xiaoli; Xu, Na; Li, Weiming; Du, Xin; Weng, Jianyu; Lin, Hai; Liang, Rong; Chen, Chunyan; Zhu, Huanling; Pan, Ling; Yang, Yun-fan; Wang, Xiaodong; Li, Guohui; Liu, Zhuogang; Liu, Zhenfang; Hu, Jianda; Liu, Chunshui; Fei, Li; Yang, Wei; Meng, Li; Gale, Robert Peter; Huang, Xiao Jun; Jiang, Qian |
| 15-Nov-2022 | Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia | Zhang, Xiaoshuai; Liu, Bingcheng; Huang, Jian; Zhang, Gongli; Liu, Xiaoli; Xu, Na; Li, Weiming; Du, Xin; Weng, Jianyu; Lin, Hai; Liang, Rong; Chen, Chunyan; Zhu, Huanling; Pan, Ling; Yang, Yunfan; Wang, Xiaodong; Li, Guohui; Liu, Zhuogang; Liu, Zhenfang; Hu, Jianda; Liu, Chunshui; Fei, Li; Yang, Wei; Meng, Li; Gale, Robert Peter; Huang, Xiao Jun; Jiang, Qian |
